3.14

0.00% 0.00

Esperion Therapeutics Inc (ESPR)

Overview News Price History Option Chain Financials Why ESPR Down? Discussions Forecast Stock Split

Esperion Therapeutics Inc stock is traded at $3.14, with a volume of 7.42M. It is up +0.00% in the last 24 hours and up +34.76% over the past month. Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Previous Close:

$3.14

Open:

$3.14

24h Volume:

7.42M

Relative Volume:

0.77

Market Cap:

$808.34M

Revenue:

$403.14M

Net Income/Loss:

$-22.68M

P/E Ratio:

-14.99

EPS:

-0.2095

Net Cash Flow:

$-13.09M

1W Performance:

+0.96%

1M Performance:

+34.76%

6M Performance:

+18.05%

1Y Performance:

+251.70%

1-Day Range:

$3.14

$3.15

1-Week Range:

$3.10

$3.18

52-Week Range:

$0.6925

$4.175

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name

Esperion Therapeutics Inc

Sector

Healthcare (1111)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

734-887-3903

Address

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Employee

294

Twitter

@esperioninc

Next Earnings Date

2026-05-07

Latest SEC Filings

ESPR's Discussions on Twitter

Compare ESPR vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESPR Esperion Therapeutics Inc	3.14	808.34M	403.14M	-22.68M	-13.09M	-0.2095
TAK Takeda Pharmaceutical Co Adr	16.46	52.00B	29.85B	776.90M	4.35B	0.2408
TEVA Teva Pharmaceutical Industries Ltd Adr	35.73	41.60B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.11	40.43B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	82.83	34.72B	9.47B	2.67B	2.28B	6.0218
UTHR United Therapeutics Corp	564.94	23.98B	3.18B	1.33B	1.04B	27.90

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-25	Initiated	Piper Sandler	Overweight
Dec-18-24	Initiated	Goldman	Neutral
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-27-23	Resumed	BofA Securities	Neutral
Feb-24-23	Upgrade	Jefferies	Hold → Buy
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform
May-05-22	Upgrade	JP Morgan	Underweight → Neutral
Mar-10-22	Initiated	H.C. Wainwright	Buy
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
May-05-21	Downgrade	Stifel	Buy → Hold
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight
Feb-12-21	Downgrade	Jefferies	Buy → Hold
Feb-09-21	Downgrade	Goldman	Neutral → Sell
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-10-20	Upgrade	Credit Suisse	Neutral → Outperform
Sep-29-20	Resumed	JP Morgan	Underweight
Aug-11-20	Downgrade	Credit Suisse	Outperform → Neutral
Apr-01-20	Resumed	BofA/Merrill	Buy
Mar-17-20	Upgrade	Citigroup	Neutral → Buy
Feb-24-20	Downgrade	Northland Capital	Outperform → Market Perform
Feb-14-20	Downgrade	Citigroup	Buy → Neutral
Sep-16-19	Upgrade	Goldman	Sell → Neutral
May-29-19	Downgrade	Goldman	Neutral → Sell
May-06-19	Upgrade	BofA/Merrill	Underperform → Neutral
Apr-26-19	Upgrade	Goldman	Sell → Neutral
Mar-13-19	Upgrade	JP Morgan	Underweight → Neutral
Jan-07-19	Reiterated	Needham	Strong Buy
Dec-13-18	Initiated	Goldman	Sell
Oct-29-18	Upgrade	Northland Capital	Market Perform → Outperform
Oct-16-18	Initiated	BTIG Research	Buy
Aug-17-18	Upgrade	Citigroup	Neutral → Buy
Jul-11-18	Downgrade	Northland Capital	Outperform → Market Perform
May-03-18	Downgrade	JP Morgan	Neutral → Underweight
May-02-18	Downgrade	BofA/Merrill	Buy → Underperform

View All

Esperion Therapeutics Inc Stock (ESPR) Latest News

May 08, 2026

Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 08, 2026

United StatesGoodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED - Mondaq

May 07, 2026

May 06, 2026

Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

May 06, 2026

MSN Money - MSN

May 06, 2026

Esperion Therapeutics Q1 2026 earnings preview - MSN

May 06, 2026

May 05, 2026

BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com

May 05, 2026

Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail

May 05, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 05, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.

May 05, 2026

BioPharma Credit to Finance Archimed's Purchase of Biotech Growth Trust's Esperion Therapeutics - Moomoo

May 05, 2026

Esperion to be acquired by ARCHIMED - The Pharma Letter

May 05, 2026

May 04, 2026

Esperion Therapeutics Cut to Hold From Buy by Needham - Moomoo

May 04, 2026

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal

May 04, 2026

Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo

May 04, 2026

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo

May 04, 2026

Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com

May 04, 2026

Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders? - Sahm

May 04, 2026

May 03, 2026

ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade

May 03, 2026

May 02, 2026

Penny Stocks To Watch TodayMay 2nd - MarketBeat

May 02, 2026

ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com

May 02, 2026

A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo

May 02, 2026

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

May 02, 2026